Get access

Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease

Authors

  • Prithiva Navan MRCP,

    1. Division of Neurosciences and Psychological Medicine, Imperial College School of Medicine, Charing Cross Hospital Campus, London, United Kingdom
    Search for more papers by this author
  • Leslie J. Findley MD, FRCP,

    1. Essex Centre for Neurological Sciences, Havering Hospital NHS Trust, Essex, United Kingdom
    Search for more papers by this author
  • Jim A. R. Jeffs,

    1. The Statistical Consultancy Service, Department of Epidemiology and Public Health, Imperial College, London, United Kingdom
    Search for more papers by this author
  • Ronald K. B. Pearce PhD, FRCP,

    1. Division of Neurosciences and Psychological Medicine, Imperial College School of Medicine, Charing Cross Hospital Campus, London, United Kingdom
    Search for more papers by this author
  • Peter G. Bain MD, FRCP

    Corresponding author
    1. Division of Neurosciences and Psychological Medicine, Imperial College School of Medicine, Charing Cross Hospital Campus, London, United Kingdom
    • Department of Neurosciences, Imperial College School of Medicine, Charing Cross Hospital, London W6 8RF, United Kingdom
    Search for more papers by this author

Abstract

Tremor is one of the cardinal signs of Parkinson's disease (PD) but its response to antiparkinsonian medication is variable. It has been postulated that pramipexole may have a stronger antiparkinsonian tremor effect than pergolide, another direct acting dopamine agonist medication, possibly because the former has preferential affinity for the dopamine D3 receptor. The purpose of this pilot study was to compare the effects of a single oral dose of either pramipexole (Pr) or pergolide (Pe) or placebo (Pl) on parkinsonian tremor and the motor (part III) subsection of the UPDRS. Ten patients (6 men, 4 women), mean age 65.3 years, mean duration from diagnosis of 2.6 years, with tremor dominant PD were recruited. On three separate occasions a single dose of pramipexole (salt) 500 μg, pergolide 500 μg or placebo were administered in random order to each patient, who were pretreated with domperidone and had their antiparkinsonian medication withheld from midnight before study. After each medication patients were assessed at baseline and then every 30 min for 4 hr using a 0 to 10 tremor rating scale and the UPDRS (part III) in a double-blind protocol. Adverse effects were systematically recorded. The results demonstrate that 500 μg of either pramipexole or pergolide reduced PD rest tremor scores to a similar degree, which at peak effect was significantly greater than placebo (respectively Pe v Pl: P < 0.006, Pr v Pl: P < 0.033). The two active drugs also had weaker beneficial effects on the UPDRS part III. Pergolide, however, was significantly more likely than pramipexole to cause nausea (P = 0.005) or vomiting (P = 0.014). © 2002 Movement Disorder Society

Get access to the full text of this article

Ancillary